Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609964 | 0.88 | KDM4E (0.42) | KDM4EALDH1A1POLBGLASMN1; SMN2 | |
| SCHEMBL3604031 | 0.85 | GAA (0.36) | POLBGLARAB9ASMN1; SMN2MAPT | |
| SCHEMBL3597635 | 0.83 | ALDH1A1 (0.39) | KDM4EALDH1A1POLBGLARECQL | |
| SCHEMBL3911826 | 0.80 | KDM4E (0.37) | KDM4EALDH1A1POLBGLAMAPT | |
| SCHEMBL13404301 | 0.74 | POLB (0.52) | KDM4EALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL3599843 | 0.73 | AR (0.40) | KDM4EALDH1A1POLBGLAMAPT | |
| SCHEMBL3596100 | 0.70 | RXRA (0.43) | KDM4EPOLBGLAMAPTXDH | |
| SCHEMBL4303748 | 0.70 | KMT2A (0.39) | KDM4EALDH1A1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3914123 | 0.70 | VCAM1 (0.43) | KDM4EALDH1A1SMN1; SMN2VCAM1MAPT | |
| SCHEMBL3600090 | 0.69 | AR (0.37) | KDM4EALDH1A1POLBGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
| EP-2032555-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | Novartis AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007144127-A1 | PYRROLE DERIVATIVES WITH CRTH2 RECEPTOR MODULATOR ACTIVITY | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | KDM4E 1399/4885ALDH1A1 439/4885POLB 441/4885 |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | KDM4E 2754/4885ALDH1A1 3117/4885POLB 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.